Elicera Therapeutics AB Earnings Call Transcripts

Fiscal Year 2025

Investor Update

Promising early clinical results were reported for the lead CAR-T program, with a complete response in the first patient and mild side effects. The company secured funding to support operations through 2027, expects multiple clinical data readouts in 2025, and is pursuing partnerships and licensing for its ITANK platform.

Read full transcript →